- Home
- IAC vs DNLI Comparison
IAC vs DNLI Comparison
Compare IAC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAC | DNLI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IAC | DNLI |
|---|---|---|
| Price | $40.40 | $18.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $47.91 | $34.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,365,235,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.48 | $408.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.56 | $12.58 |
| 52 Week High | $45.82 | $23.77 |
Technical Indicators
Market Signals| Indicator | IAC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 46.35 |
| Support Level | $38.29 | $18.86 |
| Resistance Level | $40.60 | $20.40 |
| Average True Range (ATR) | 1.37 | 0.99 |
| MACD | -0.47 | -0.08 |
| Stochastic Oscillator | 12.91 | 42.96 |
Price Performance
Historical ComparisonAbout IAC IAC Inc.
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.